Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability and efficacy of TIN816 to prevent acute kidney injury after cardiac surgery
2022-000794-47Phase 2Active
- Sponsor
- Novartis
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute kidney failure (AKF) comparing TIN816 with Placebo (2 arms). Started Oct 2022; status: active.
02
Drugs
TIN-816
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on 2022-000794-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000794-47.